If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Knowbe4, Inc. (KNBE)
Zymergen Inc. (ZY)
Neuropace Inc (NPCE)
Upcoming IPO
Agiliti, Inc (AGTI)
Treace Medical Concepts, Inc. (TMCI)
Latham Group, Inc. (SWIM)
Rain Therapeutics Inc. (RAIN)
Impel Neuropharma, Inc. (IMPL)
Ftc Solar, Inc. (FTCI)
Aveanna Healthcare Holdings Inc. (AVAH)
Endeavor Group Holdings (EDR)
The Fortegra Group, Inc. (FRF)
Privia Health Group, Inc. (PRVA)
Priced IPO
Uipath Inc (PATH)
Doubleverify Holdings, Inc. (DV)
Skywater Technology, Inc. (SKYT)
Infobird (IFBD)
Troika Media Group, Inc. (TRKA)
Biomea Fusion, Inc. (BMEA)
Akoya Biosciences, Inc. (AKYA)
Recursion Pharmaceuticals, Inc. (RXRX)
Karat Packaging Inc. (KRT)
AppLovin (APP)
Esports Technologies (EBET)
Agilon Health, Inc. (AGL)
TuSimple Holdings Inc (TSP)
Coinbase Global, Inc. (COIN)
Alkami Technology, Inc. (ALKT)
Reneo Pharmaceuticals, Inc. (RPHM)
Vectivbio Holding Ag (VECT)
UTime Limited (UTME)
Frontier Group Holdings (ULCC)
Compass, Inc. (COMP)
More companies

Finch Therapeutics Group, Inc. (FNCH)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage microbiome therapeutics company leveraging their Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to their health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to immune disorders, infections, neurological conditions, cancer and other serious diseases. They are developing novel therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. Their Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Their lead product candidate, CP101, delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection, or CDI. In June 2020, they reported positive topline data from their first of two pivotal trials in recurrent CDI, and they plan to initiate a Phase 3 clinical trial, which they refer to as PRISM4, as their second pivotal trial of CP101 for recurrent CDI in mid-2021.
Biological Products (no Diagnostic Substances)
Mark Smith Gregory D. Perry
Employees Founded
131 2014


Address: 200 Inner Belt Road, Suite 400 Somerville, Massachusetts 02143

Telephone: (617) 229-6499

Web page:

IPO information

First Trade Date 3/19/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 6.25
Shares Revised (MM) 7.5
Expected offer amount (MM) $100
Realized offer amount(MM) $127.5

Financial Data (last reporting year)

Market Cap (MM) $734.4
Revenues (MM) $7.72
Net Income (Loss) (MM) $-39.34


What do you think will happen with the FNCH share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: BofA Securities

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
BofA Securities/ Jefferies/ Evercore ISI

Sector: Healthcare

Tweets about $FNCH

Tweets volume:

RT volume:


Google Trends Stats